PER — Percheron Therapeutics Cashflow Statement
0.000.00%
- AU$9.79m
- -AU$0.36m
- AU$0.37m
Annual cashflow statement for Percheron Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Changes in Working Capital | 0.705 | 0.588 | 2.14 | 2.16 | 2.76 |
Other Operating Cash Flow | |||||
Cash from Operating Activities | -5.83 | -7.81 | -8.15 | -10.1 | -15.6 |
Capital Expenditures | -0.008 | -0.004 | -0.029 | -0.004 | -0.007 |
Purchase of Fixed Assets | |||||
Cash from Investing Activities | -0.008 | -0.004 | -0.029 | -0.004 | -0.007 |
Financing Cash Flow Items | -0.614 | -1.49 | 0 | -0.503 | -0.865 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 7.8 | 21 | -0.085 | 11 | 14 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 1.96 | 13.2 | -8.27 | 0.899 | -1.7 |